A guide to improving rare disease clinical research through ethical design, operational excellence, and patient-centered innovation
This white paper explores the unique challenges of rare disease clinical research when conducted in pediatric populations where there is limited patient availability, delays in diagnosis, and geographically dispersed patient pools. In these instances, every interaction with the patient must be scientifically and ethically justified. Trial designs need to balance data generation and study integrity whilst ensuring minimal burden on this vulnerable population. As a result, these trials require adaptive, patient-centric approaches that ensure every sample and data point is used to deliver meaningful outcomes.
With a strong focus on the evolving landscape of rare disease clinical trials, this paper emphasizes how modeling & simulation can help transform limited datasets into actionable insights. These model-informed strategies enable optimal dose selection, efficient sampling, and reduced trial size, helping biopharma reduce the need for complicated or invasive procedures while ensuring data quality. Utilizing prior data from volunteers in other studies and applying model-based extrapolation enables the acceleration of rare disease clinical research with reduced timelines and less strain on the patients.
This paper further emphasizes the necessity for ethical oversight, robust regulatory strategy, and patient collaboration in advancing rare disease clinical research. Regulators expect clear justification for all study endpoints, samples, and procedures. Collaboration between biopharma, patient advocacy groups and families, as well as clinical research partners is essential to ensure that studies are feasible and impactful. As the landscape for rare diseases continues to evolve, integration of model-driven approaches, digital health technologies, and a patient-centered design are critical to accelerating the development of these much-needed therapies.
Request a Proposal
Share This
